

Competitive Pipeline Report — Johnson & Johnson

Run date (UTC): 2026-01-08

Source URL	https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf
Stored PDF	sources/jnj/2026-01-08.pdf
SHA256	7be7a71814f547e8772f826b14552f40244c9d6a9dd0548d8b79a85c3f1a9e04
Extracted 'as of' date	October 14, 2025
Programs extracted	101
Recovered baseline	No
Doc unchanged / reused	Yes
Full inventory (CSV)	reports/jnj/2026-01-08.programs.csv

Executive summary

No pipeline update detected

The source pipeline PDF is unchanged since the last valid snapshot (same SHA256). This report reuses the prior extracted snapshot to avoid false differences caused by extraction variability.

Note: Source PDF unchanged; reused prior snapshot to avoid extraction variability.

Pipeline snapshot (counts by phase)

Phase	Count
Unknown	101
Total	101

Change log (previous vs current)

Confidence score (0–1): 0.35

New / Added items

None detected.

Removed / Discontinued items

None detected.

Phase changes

None detected.

Appendix — Full pipeline inventory

Each row includes the source page number for manual verification.

Asset	Indication	Phase	Page
AKEEGA (niraparib/abiraterone)	M1 Metastatic Castration-Sensitive Prostate Cancer		
Bleximenib	Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine		
Bleximenib	Relapsed Refractory Acute Myeloid Leukemia		
CABENUVA	HIV Adolescents		
CAPLYTA (lumateperone)	Adjunctive Treatment for Major Depressive Disorder		
CAPLYTA (lumateperone)	Bipolar Mania		
CAPLYTA (lumateperone)	Pediatric Psychiatric Indications		
CARVYKTI (Ciltacabtagene autoleucel)	Frontline Multiple Myeloma TNI		
CARVYKTI (Ciltacabtagene autoleucel)	Frontline Multiple Myeloma Transplant Eligible vs ASCT		
DARZALEX (daratumumab)	Smoldering Multiple Myeloma		
DARZALEX (daratumumab)	Frontline multiple myeloma transplant ineligible		
ERLEADA (apalutamide)	Localized Prostate Cancer		
ERLEADA (apalutamide)	High Risk Prostate Cancer		
IMAAVY (nipocalimab)	Generalized Myasthenia Gravis		
IMAAVY (nipocalimab)	Generalized Myasthenia Gravis Pediatrics		
IMBRUVICA (ibrutinib)	Frontline Chronic Lymphocytic Leukemia (I + V fixed duration)		
IMBRUVICA (ibrutinib)	Frontline Mantle Cell Lymphoma		
INLEXZO (gemcitabine intravesical system)	Non Muscle Invasive Bladder Cancer		
INLEXZO (gemcitabine intravesical system)	Non Muscle Invasive Bladder Cancer BCG-naïve High Risk		
INLEXZO (gemcitabine intravesical system)	High Risk Non Muscle Invasive Bladder Cancer BGC Experienced		
ITI-1284	Generalized Anxiety Disorder		
ITI-1284	Alzheimer's Disease-Related Psychosis		
ITI-1284	Alzheimer's Disease-Related Agitation		
JNJ-0387	Solid Tumors		
JNJ-0631 (ARX305)	Renal Cancer		
JNJ-0683 (ARX788)	Breast Cancer		
JNJ-1493	Hematological Malignancies		
JNJ-1887 sCD59	Geographic Atrophy		
JNJ-1900 (NBTXR3)	Head and Neck Cancer		
JNJ-1900 (NBTXR3)	Lung Cancer		
JNJ-2056 (tau active immunotherapy)	Alzheimer's Disease		
JNJ-2638	Gastrointestinal Cancer		
JNJ-2761	Multiple Myeloma		

Asset	Indication	Phase	Page
JNJ-3413	Lymphoma		
JNJ-4496	Hematological Malignancies		
JNJ-4680	Lung Cancer		
JNJ-4681	Hematological Malignancies		
JNJ-4804 Co-antibody Therapy	Ulcerative Colitis		
JNJ-4804 Co-antibody Therapy	Psoriatic Arthritis		
JNJ-4804 Co-antibody Therapy	Crohn's Disease		
JNJ-4916	Lung Cancer		
JNJ-5108	Immunological Diseases		
JNJ-5120	Major Depressive Disorder		
JNJ-5322	Multiple Myeloma		
JNJ-5939	Atopic Dermatitis		
JNJ-6420	Prostate Cancer		
JNJ-6848	Immunological Diseases		
JNJ-7446	Lung Cancer		
JNJ-7528	Atopic Dermatitis		
JNJ-8177 (ARX517)	Prostate Cancer		
JNJ-8377	Lymphoma		
JNJ-8543	Hematological Malignancies		
JNJ-9401	Prostate Cancer		
JNJ-9530	Hematological Malignancies		
JNJ-9892	Hematological Malignancies		
JNJ-9968	Hematological Malignancies		
RPGR Gene Therapy	Retinitis Pigmentosa		
RYBREVANT (amivantamab)	Frontline Non Small Cell Lung Cancer in combination with chemotherapy		
RYBREVANT (amivantamab)			
RYBREVANT (amivantamab)	Colorectal Cancer		
RYBREVANT (amivantamab)	Colorectal Cancer 2L		
SIMPONI (golimumab)	Pediatric Ulcerative Colitis		
SIRTURO	Leprosy		
SIRTURO	Tuberculosis Long Acting		
SPRAVATO (esketamine)	Treatment Resistant Depression monotherapy		
SPRAVATO (esketamine)	Major Depressive Disorder with Suicidal Ideation Pediatrics		
STELARA (ustekinumab)	Pediatric Crohn's Disease		
STELARA (ustekinumab)	Pediatric Ulcerative Colitis		
TALVEY (talquetamab)	Relapsed Refractory Multiple Myeloma CD38 exposed		

Asset	Indication	Phase	Page
TALVEY (talquetamab)	Relapsed Refractory Multiple Myeloma A-CD38 Naïve		
TALVEY + TECVAYLI	Relapsed Refractory Multiple Myeloma CD38 exposed		
TALVEY + TECVAYLI	TIE NDMM in combination with DR		
TALVEY + TECVAYLI	Relapsed Refractory Multiple Myeloma		
TAR-210 (RIS/erdafitinib)	Intravesical Delivery System for Localized Bladder Cancer		
TECVAYLI (teclistamab)	Multiple Myeloma 1-3PLs		
TECVAYLI (teclistamab)	TE NDMM maintenance		
TECVAYLI (teclistamab)	TIE NDMM in combination with DR		
TECVAYLI (teclistamab)	Relapsed Refractory Multiple Myeloma CD38 exposed		
TREMFYA (guselkumab)	Pediatric Juvenile Psoriatic Arthritis		
TREMFYA (guselkumab)	Pediatric Psoriasis		
TREMFYA (guselkumab)	Psoriatic Arthritis Structural Damage		
TREMFYA (guselkumab)	Ulcerative Colitis Subcutaneous Induction		
TREMFYA (guselkumab)	Pediatric Ulcerative Colitis		
UPTRAVI (selexipag)	Pediatric Pulmonary Arterial Hypertension		
icotrokinra	Psoriasis		
icotrokinra	Psoriatic Arthritis		
icotrokinra	Ulcerative Colitis		
macitentan	Pulmonary Arterial Hypertension 75mg		
milvexian (Factor Xla)	Secondary Stroke Prevention		
milvexian (Factor Xla)	Acute Coronary Syndrome		
milvexian (Factor Xla)	Atrial Fibrillation		
nipocalimab	Warm Autoimmune Hemolytic Anemia		
nipocalimab	Sjogren's Disease		
nipocalimab	Hemolytic Disease of the Fetus and Newborn		
nipocalimab	Fetal and Neonatal Alloimmune Thrombocytopenia		
nipocalimab	Systemic Lupus Erythematosus		
nipocalimab	Idiopathic Inflammatory Myopathy		
nipocalimab	Chronic Inflammatory Demyelinating Polyneuropathy		
pasritamig	Prostate Cancer		
posdinemab	Alzheimer's Disease		
seltorexant	Adjunctive Treatment for Major Depressive Disorder with Insomnia Symptoms		